C. Barone

1.1k total citations
19 papers, 682 citations indexed

About

C. Barone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, C. Barone has authored 19 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in C. Barone's work include Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (5 papers). C. Barone is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (9 papers) and Cancer Treatment and Pharmacology (5 papers). C. Barone collaborates with scholars based in Italy, United States and France. C. Barone's co-authors include Alberto Sobrero, Laura A. Cisar, Laurence Collette, Philippe Rougier, Bernard Nordlinger, David Cunningham, Robert Manges, Armando Santoro, Enrique Aranda and Sylvie Assadourian and has published in prestigious journals such as Journal of Clinical Oncology, Annals of the New York Academy of Sciences and British Journal of Cancer.

In The Last Decade

C. Barone

18 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Barone Italy	7	516	223	179	165	145	19	682
Alberto F. Sobrero Italy	15	578 1.1×	224 1.0×	130 0.7×	151 0.9×	126 0.9×	66	697
Jean‐Marc Ferraz France	9	447 0.9×	201 0.9×	99 0.6×	186 1.1×	150 1.0×	19	652
Ayako Mizota Japan	9	387 0.8×	260 1.2×	173 1.0×	187 1.1×	84 0.6×	16	589
Yasuyuki Kawamoto Japan	13	399 0.8×	210 0.9×	222 1.2×	117 0.7×	128 0.9×	68	530
Rita P. Dalal United States	10	415 0.8×	311 1.4×	144 0.8×	88 0.5×	88 0.6×	21	622
Huann‐Sheng Wang Taiwan	12	521 1.0×	146 0.7×	161 0.9×	210 1.3×	101 0.7×	34	686
Claire Greene United States	5	392 0.8×	194 0.9×	114 0.6×	158 1.0×	209 1.4×	8	511
Katia Dotti Italy	12	364 0.7×	149 0.7×	99 0.6×	114 0.7×	56 0.4×	28	514
Werner Freier Germany	15	513 1.0×	360 1.6×	117 0.7×	99 0.6×	129 0.9×	28	760
Holly Kemberling United States	7	471 0.9×	154 0.7×	125 0.7×	185 1.1×	118 0.8×	9	567

Countries citing papers authored by C. Barone

Since Specialization

Citations

This map shows the geographic impact of C. Barone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Barone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Barone more than expected).

Fields of papers citing papers by C. Barone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Barone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Barone. The network helps show where C. Barone may publish in the future.

Co-authorship network of co-authors of C. Barone

This figure shows the co-authorship network connecting the top 25 collaborators of C. Barone. A scholar is included among the top collaborators of C. Barone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Barone. C. Barone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Pinto, Carmine, Armando Orlandi, Nicola Normanno, et al.. (2024). Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study. Journal of Clinical Oncology. 42(11). 1278–1287. 5 indexed citations

Decaens, Thomas, C. Barone, Eric Assénat, et al.. (2021). Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer. 125(2). 190–199. 28 indexed citations

Reichardt, Peter, M. Schlemmer, Zsuzsanna Pápai, et al.. (2019). Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting. Oncology Research and Treatment. 42(12). 629–635. 2 indexed citations

Perisano, Carlo, Rosa Ma, Fabrizio Donati, C. Barone, & Giulio Maccauro. (2018). Treatment options of simple bone cysts: the role of bone substitutes, growth factors and literature review.. PubMed. 30(4 Suppl 1). 159–164. 2 indexed citations

Decaens, Thomas, C. Barone, Eric Assénat, et al.. (2018). Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). Annals of Oncology. 29. viii235–viii235. 6 indexed citations

Ciardiello, Fortunato, Lisa Salvatore, Stefano Cascinu, et al.. (2016). Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. Annals of Oncology. 27. iv44–iv44.

Salvatore, Lisa, Fortunato Ciardiello, Stefano Cascinu, et al.. (2016). Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Annals of Oncology. 27. iv47–iv47. 1 indexed citations

Sobrero, Alberto, Luciano Latini, C. Barone, et al.. (2015). Review of RAISE, a Randomized, Double-Blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (RAM) or Placebo (PBO) in Patients (pts) With Metastatic Colorectal Carcinoma (mCRC) Progressive During or Following First-Line Combination Therapy With Bevacizumab (bev), Oxaliplatin (ox), and a Fluoropyrimidine (fp): Primary Results and Subgroup Analysis by KRAS Status. Annals of Oncology. 26. vi37–vi37. 1 indexed citations

Rougier, Philippe, Hanno Riess, Robert Manges, et al.. (2013). Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European Journal of Cancer. 49(12). 2633–2642. 145 indexed citations

10.

Bendell, Johanna C., C. Tournigand, Anna Świeboda-Sadlej, et al.. (2011). Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(4_suppl). 478–478. 12 indexed citations

11.

Cutsem, Eric Van, Roberto Labianca, G. Bodoky, et al.. (2009). Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. Journal of Clinical Oncology. 27(19). 3117–3125. 298 indexed citations

12.

Pozzo, Carmelo, C. Barone, & Nancy E. Kemeny. (2008). Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treatment Reviews. 34(4). 293–301. 22 indexed citations

13.

Barone, C., et al.. (2008). Aesthetic outcomes in breast conservation therapy. Aesthetic Surgery Journal. 28(2). 165–170. 68 indexed citations

14.

Barone, C., et al.. (2007). Outpatient extended abdominoplasty in the patient with massive weight loss. Aesthetic Surgery Journal. 27(2). 129–136. 5 indexed citations

15.

Dank, Magdolna, J. Załuski, C. Barone, et al.. (2005). Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1^st-line advanced gastric cancer patients. Journal of Clinical Oncology. 23(16_suppl). 4003–4003. 73 indexed citations

16.

Pozzo, Carmelo, Seppo Pyrhönen, I. Bodrogi, et al.. (1999). A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC). European Journal of Cancer. 35. S70–S70. 5 indexed citations

17.

Barone, C., Carmelo Pozzo, Hans Starkhammar, et al.. (1997). CPT11 alternating with 5 fluorouracil (5 FU) folinic acid (FA): A multicentre phase II study in 1st line chemotherapy (CT) of metastatic colorectal cancer (CRC): Preliminary results. European Journal of Cancer. 33. S169–S170. 6 indexed citations

18.

Rosso, R., G. Gardin, P. Pronzato, et al.. (1993). The Role of Lonidamine in the Treatment of Breast Cancer Patients. Annals of the New York Academy of Sciences. 698(1). 349–356. 2 indexed citations

19.

Grieco, Antonio, et al.. (1984). [Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). A non-controlled study].. PubMed. 110(4). 353–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact